AI
Tuesday, April 17, 2018 8:31:49 AM
ARQL - 2.70 Pre-market now at 2.80/2.88
Basilea Licenses Late-stage Oncology Drug candidate Derazantinib from ArQule
BZ: ArQule Licenses Derazantinib to Basilea Pharma for Development and Commercialization Outside of China, Will Receive a $10M Upfront Payment and Up to $326M in Milestones
Basilea Licenses Late-stage Oncology Drug candidate Derazantinib from ArQule
BZ: ArQule Licenses Derazantinib to Basilea Pharma for Development and Commercialization Outside of China, Will Receive a $10M Upfront Payment and Up to $326M in Milestones
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
